BiotechTube

AzaSite + Tobramycin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacterial Conjunctivitis

Conditions

Bacterial Conjunctivitis

Trial Timeline

Jul 1, 2004 → Oct 1, 2005

NCT ID
NCT00105469

About AzaSite + Tobramycin

AzaSite + Tobramycin is a phase 3 stage product being developed by Merck for Bacterial Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00105469. Target conditions include Bacterial Conjunctivitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00105469Phase 3Completed

Competing Products

20 competing products in Bacterial Conjunctivitis

See all competitors
ProductCompanyStageHype Score
ASP3652 + PlaceboAstellas PharmaPhase 2
52
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Xeruborbactam + Cefiderocol + Xeruborbactam/Cefiderocol + Dextrose 5% in waterShionogiPhase 1
33
CefiderocolShionogiPre-clinical
23
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol/XeruborbactamShionogiPhase 1
33
DoripenemJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
85
doripenemJohnson & JohnsonPhase 3
77
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
HRS-8427Jiangsu Hengrui MedicinePhase 1
33
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4AbbViePhase 2
52
DalbavancinAbbViePhase 1
33
V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™MerckPhase 3
77
AzaSiteMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85